Real-world data from 2016 to 2025 highlight the changing landscape of biologic use and the growing preference for tezepelumab in asthma.
Asthma biologic use was not associated with an increase in respiratory infection risk, according to results from the 2026 AAAAI Annual Meeting.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results